Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension

NCT02466490 is registered in ClinicalTrials.gov with Stendhal Americas, S.A. as lead sponsor.

NCT NCT02466490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02466490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension
Lead sponsor
Stendhal Americas, S.A.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
February 28, 2014
Enrollment
272 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, essential